期刊文献+

原癌基因c-fos在人乳腺癌耐药株MCF-7/ADR中的表达及意义 被引量:1

Expression and significance of the proto-oncogene c-fos in human breast cancer multidrug resistant MCF-7/ADR cells
下载PDF
导出
摘要 目的探讨原癌基因c-fos在人乳腺癌细胞MCF-7/ADR多药耐药形成中的作用。方法采用MTT法测定化疗药物阿霉素(adriamycin,ADR)、紫杉醇、依托泊甙对人乳腺癌敏感株MCF-7和耐药株MCF-7/ADR的IC_(50);用real time PCR法检测MCF-7/ADR和MCF-7的c-fos mRNA表达差异;用逆转录PCR(RT-PCR)和Western blot法检测ADR对MCF-7中c-fos mRNA和蛋白表达的诱导作用。结果相对于MCF,MCF-7/ADR对ADR、紫杉醇、依托泊甙的耐药倍数分别为39.94,102.34和12.16;MCF-7/ADR中c-fos mRNA表达明显高于MCF-7;ADR可诱导MCF-7中c-fos mRNA和蛋白呈时间依赖性表达。结论 c-fos在MCF-7/ADR多药耐药中起重要作用,有可能成为耐药肿瘤诊断和治疗的新分子靶点。 Objective To explore the effect of the proto-oncogene c-fos on multidrug resistance(MDR)of human breast cancer MCF-7/ ADR cells.Methods MTT assay was used to elucidate IC_(50)values of adriamycin(ADR),paclitaxel and etoposide against breast cancer cells.The expression of c-fos mRNA in MCF-7 and MCF-7/ADR cells was determined using real time PCR.The induction of cfos mRNA and protein by ADR in MCF-7 cells was examined by reverse transcriptase-PCR and Western blot,respectively.Results Compared with MCF-7,the resistance fold of ADR,paclitaxel and etoposide against MCF-7/ADR was 39.94,102.34 and 12.16,respectively. The level of c-fos mRNA in MCF-7/ADR was significantly higher than that in MCF-7 cells(P0.01).The expression of c-fos mRNA and protein was induced by ADR in a time-dependent manner in MCF-7.Conclusion The results suggest that the proto-oncogene c-fos may play an important role in MDR of MCF-7/ADR cells,and it would be a novel molecular target for the diagnosis and treatment of breast cancer.
出处 《山西医科大学学报》 CAS 2012年第10期731-734,共4页 Journal of Shanxi Medical University
基金 2012年山西医科大学基础医学院331科技培植基金资助项目 山西医科大学博士启动基金资助项目(055169)
关键词 C-FOS 多药耐药 分子靶点 c-fos multidrug resistance(MDR) molecular target
  • 相关文献

参考文献9

  • 1Wong ST, Goodin S. Overcoming drug resistance in patients with metastatic breast cancer [ J ]. Pharmacotherapy, 2009,29 ( 8 ) : 954 - 965.
  • 2Zhang X, Huang X, Olumi AF. Repression of NF-kappaB and acti- vation of AP-1 enhance apoptosis in prostate cancer cells [ J]. Int J Cancer,2009,124 ( 8 ) : 1980 - 1989.
  • 3Jabr-Milane LS, van Vlerken LE, Yadav S, et al. Multi-functional nanocarriers to overcome tumor drug resistance [ J ]. Cancer Treat Rev,2008,34 ( 7 ) :592 - 602.
  • 4Mahner S, Baasch C,Schwarz J,et al. C-los expression is a molecu- lar predictor of progression and survival in epithelial ovarian carci- noma [ J]. Br J Cancer,2008,99 ( 8 ) : 1269 - 1275.
  • 5Bland KI, Konstadoulakis MM, Vezeridis MP, et al. Oncogene pro- tein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prog- nostic discriminants for breast carcinoma [ J ]. Ann Surg, 1995,221 (6) :706 -720.
  • 6Arteaga CL, Holt JT. Tissue-targeted antisense c-fos retroviral vec- tor inhibits established breast cancer xenografts in nude mice [ J]. Cancer Res, 1996,56 (5) : 1098 - 1103.
  • 7Bonovich M, Olive M, Reed E,et al. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines [ J ]. Cancer Gene Ther, 2002,9 ( 1 ) : 62 - 70.
  • 8Moorehead RA, Singh G. Influence of the proto-oncogene c-fos on cisplatin sensitivity [ J ]. Biochem Pharmacol, 2000,59 ( 4 ) : 337 - 345.
  • 9Yap TA, Workman P. Exploiting the cancer genome : strategies for the discovery and clinical development of targeted molecular thera- peutics [ J ]. Annu Rev Pharmacol Toxicol,2012 ,52 :549 - 573.

同被引文献9

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部